Clinical trial
A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome
NCT00274781 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome
- Lead sponsor
- The Cleveland Clinic
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 29, 2004
- Completion date
- November 30, 2010
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.